Top

Published in:

01-11-2009 | Brief Report

A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer

Authors: Natalia Bogdanova, Cezary Cybulski, Marina Bermisheva, Ihor Datsyuk, Paria Yamini, Peter Hillemanns, Natalja Nikolaevna Antonenkova, Elza Khusnutdinova, Jan Lubinski, Thilo Dörk

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

Blood relatives of patients with ataxia-telangiectasia (A-T) have an increased risk to develop breast cancer. Allelic heterogeneity has made it difficult to confirm the role of ATM, the gene mutated in A-T, for breast cancer susceptibility in the general population. We now report that a nonsense mutation, p.E1978X (c.5932G>T), is both a classical A-T mutation and a breast cancer susceptibility allele in Eastern European populations. In a case–control study from Belarus, the E1978X mutation was identified in 10/1,891 Byelorussian breast cancer cases (0.5%) compared with 1/1,019 population controls [odds ratio (OR): 5.4; 95% confidence interval (95% CI), 0.7–42.4, P = 0.1]. A second case–control study from Russia identified the E1978X mutation in two Russian and one Ukrainian cases out of 611 breast cancer patients but not in any Russian or Ukrainian controls (P = 0.1). In a third case–control study from Poland, E1978X was observed in 7/3,910 Polish breast cancer cases (0.2%) compared with 1/2,010 cancer-free population controls (OR: 3.6; 95% CI: 0.4–29.3, P = 0.4). In the combined analysis, E1978X was significantly associated with breast cancer (Mantel–Haenszel OR: 5.6, 95% CI: 1.3–21.4, P = 0.01). Taken together, this study provides first evidence for the association of a common A-T causing mutation with breast cancer in Eastern European founder populations.

Gatti RA (2002) Ataxia-telangiectasia. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 239–266

Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3(3):155–168. doi:10.1038/nrc1011 CrossRefPubMed

Swift M, Sholman L, Perry M, Chase C (1976) Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 36(1):209–215PubMed

Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316(21):1289–1294PubMed

Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325(26):1831–1836PubMed

Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92(2):130–134. doi:10.1016/S0165-4608(96)00328-7 CrossRefPubMed

Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79(7–8):1304–1307. doi:10.1038/sj.bjc.6690209 CrossRefPubMed

Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97(11):813–822PubMedCrossRef

Olsen JH, Hahnemann JM, Børresen-Dale AL et al (2005) Breast and other cancers in 1,445 blood relatives of 75 Nordic patients with ataxia-telangiectasia. Br J Cancer 93(2):260–265. doi:10.1038/sj.bjc.6602658 CrossRefPubMed

10.

Cavaciuti E, Laugé A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D et al (2005) Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosom Cancer 42(1):1–9. doi:10.1002/gcc.20101 CrossRefPubMed

11.

FitzGerald MG, Bean JM, Hegde SR et al (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15(3):307–310. doi:10.1038/ng0397-307 CrossRefPubMed

12.

Broeks A, Urbanus JH, Floore AN et al (2000) ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 66(2):494–500. doi:10.1086/302746 CrossRefPubMed

13.

Dörk T, Bendix R, Bremer M et al (2001) Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 61(20):7608–7615PubMed

14.

Thorstenson YR, Roxas A, Kroiss R et al (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63(12):3325–3333PubMed

15.

Szabo CI, Schutte M, Broeks A et al (2004) Are ATM mutations 7271T→G and IVS10-6T→G really high-risk breast cancer-susceptibility alleles? Cancer Res 64(3):840–843. doi:10.1158/0008-5472.CAN-03-2678 CrossRefPubMed

16.

Tommiska J, Jansen L, Kilpivaara O et al (2006) ATM variants and cancer risk in breast cancer patients from Southern Finland. BMC Cancer 6:209. doi:10.1186/1471-2407-6-209 CrossRefPubMed

17.

Brunet J, Gutiérrez-Enríquez S, Torres A et al (2008) ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clin Genet 73(5):465–473CrossRefPubMed

18.

Renwick A, Thompson D, Seal S et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873–875. doi:10.1038/ng1837 CrossRefPubMed

19.

Telatar M, Teraoka S, Wang Z et al (1998) Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 62(1):86–97. doi:10.1086/301673 CrossRefPubMed

20.

Sandoval N, Platzer M, Rosenthal A et al (1999) Characterization of ATM gene mutations in 66 ataxia-telangiectasia families. Hum Mol Genet 8:69–79. doi:10.1093/hmg/8.1.69 CrossRefPubMed

21.

Birrell GW, Kneebone K, Nefedov M, Nefedova E, Jartsev MN, Mitsui M et al (2005) ATM mutations, haplotype analysis, and immunological status of Russian patients with ataxia-telangiectasia. Hum Mutat 25(6):593. doi:10.1002/humu.9341 CrossRefPubMed

22.

CHEK2 Breast Cancer Case Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74(6):1175–1182. doi:10.1086/421251 CrossRef

23.

Górski B, Cybulski C, Huzarski T et al (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92(1):19–24. doi:10.1007/s10549-005-1409-1 CrossRefPubMed

24.

Heikkinen K, Rapakko K, Karppinen SM et al (2006) RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27(8):1593–1599. doi:10.1093/carcin/bgi360 CrossRefPubMed

25.

Erkko H, Xia B, Nikkilä J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319. doi:10.1038/nature05609 CrossRefPubMed

26.

Bogdanova N, Feshchenko S, Schürmann P et al (2008) Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer 122(4):802–806. doi:10.1002/ijc.23168 CrossRefPubMed

27.

Pylkäs K, Tommiska J, Syrjäkoski K et al (2007) Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis 28(5):1040–1045. doi:10.1093/carcin/bgl237 CrossRefPubMed

28.

Bernstein JL, Teraoka S, Southey MC et al (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 27(11):1122–1128. doi:10.1002/humu.20415 CrossRefPubMed

Title: A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer
Authors: Natalia Bogdanova
Cezary Cybulski
Marina Bermisheva
Ihor Datsyuk
Paria Yamini
Peter Hillemanns
Natalja Nikolaevna Antonenkova
Elza Khusnutdinova
Jan Lubinski
Thilo Dörk
Publication date: 01-11-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0189-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women

Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer

Correlates of existential well-being and their association with health-related quality of life in breast cancer survivors compared with the general population

Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer